Skip to content

Search

Elevated IL-5 and IL-13 responses to egg proteins predate the introduction of egg in solid foods in infants with eczema

Elevated egg-specific Th2 cytokine responses were established prior to egg ingestion at 4months and were not significantly altered by introduction of egg

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

The purpose of this article is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early...

Food for thought: progress in understanding the causes and mechanisms of food allergy

Treatments for food allergy are still lacking, yet progress is being made, and immunotherapy appears more effective than dietary avoidance.

Developments in the field of allergy in 2014 through the eyes of Clinical and Experimental Allergy

The pathogenesis of asthma continues to be a major topic of interest to our authors with reviews and original papers on the role of viruses, mechanisms of...

EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy

Food allergy can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments.

Epigenome-wide association study reveals longitudinally stable DNA methylation differences in CD4+ T cells from children with IgE-mediated food allergy

Food allergy is mediated by a combination of genetic and environmental risk factors, potentially mediated by epigenetic mechanisms.

Prevalence and Sociodemographic Variation of Allergic Diseases in Australia: Findings From the Australian National Health Survey

The prevalence of allergic diseases across the Australian population, in all regions and age groups, is not well documented. This study aimed to describe the prevalence and distribution of five allergic diseases (allergic rhinitis, asthma, drug allergy, eczema, and food allergy) and examine differences by sociodemographic factors. 

Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children

The first peanut oral immunotherapy (OIT) for children was approved by the US Food and Drug Administration (FDA) in 2020. While clinical efficacy is established, evidence on cost-effectiveness-whether the benefits outweigh the costs and adverse effects-remains limited. A variant of OIT, known as probiotic and peanut OIT (PPOIT), has shown similar efficacy in trials.

Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy

The high burden of peanut allergy underscores the need for treatment options that improve patient health-related quality of life (HRQL). However, the modifying effect of sex assigned at birth on treatment-related outcomes remains poorly understood. We sought to investigate whether sex modifies treatment effect on the change in overall and subdomain HRQL during the PPOIT-003 trial.